Medigene AG / Medigene AG: Notification § 27a . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Notification § 27a
Issuer information:
Name: Medigene AG
Addresse: Lochhamer Str. 11, 82152 Planegg/Martinsried
Location: Martinsried
Country: Germany
Security Code Number: A1X3W0 / A161NA
ISIN: DE000A1X3W00 / ISIN DE000A161NA3
On 22 July 2015, Aviva plc informed us in accordance with Section 27a, para.1, sentence 3 German Securities Trading Act (Wertpapierhandelsgesetz - WpHG), that Aviva plc has exceeded a 10% holding threshold in Medigene AG.
Aviva plc confirmed the following:
1. The investment is not aimed to implement strategic objectives but is aimed at generating a trading profit.
2. There are no plans to acquire further voting rights within the next twelve months by means of a purchase or by any other means.
3. It is not our objective to nominate onto or remove directors from the Board, but if we feel there are issues with board composition we would, in our engagement with the company encourage it to address any concerns we may have. We expect boards to be effective in safeguarding shareholder interests and they should have the right skills and experience to take the company's strategy forward. In particular we recognise the important (and independent) role of the chairman and non-executive directors in providing appropriate internal challenge to board discussions and decisions to ensure that all directors act in the best interests of the company. We also place particular importance on boards setting appropriate standards and values for the company both in terms of corporate responsibility and also on doing the right thing in the way companies make decisions.
4. There are no intentions to achieve a material change in the Company's capital structure, in particular as regards the ration between own funds and external funds and the dividend policy.
Within our total holding of 1,965,649 shares (10.01%) acquired on 20 July 2015, 1,478,262 shares held as a beneficial (own funds) interest (7.52%) and remaining 487,387 shares are held as a non-beneficial (external funds) interest (2.48%).
The Executive Management Board
Planegg-Martinsried, 24 July 2015
Contact Medigene AG
Public & Investor Relations
Julia Hofmann / Anja Clausnitzer
Email: investor@medigene.com
Tel.: +49 - (0)89 - 20 00 33 33 01
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medigene AG via Globenewswire
--- End of Message ---
Medigene AG
Lochhamer Strasse 11 Martinsried / München Germany
WKN: A1X3W0;ISIN: DE000A1X3W00;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
